<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033769</url>
  </required_header>
  <id_info>
    <org_study_id>IFG-06-2019</org_study_id>
    <secondary_id>2020-001938-35</secondary_id>
    <secondary_id>AGO-B-049</secondary_id>
    <nct_id>NCT05033769</nct_id>
  </id_info>
  <brief_title>Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer</brief_title>
  <acronym>AIRE</acronym>
  <official_title>AIRE - Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer - a Prospectively Randomized Phase IV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer Frauengesundheit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer Frauengesundheit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After progression of disease after one chemotherapy, metastatic breast cancer patients will&#xD;
      be randomized 1:1 to one of the following treatment arms:&#xD;
&#xD;
      Arm A. Eribulin Arm B. Paclitaxel&#xD;
&#xD;
      Blood draws for immune analysis will be performed before start of therapy, on day 1 of cycle&#xD;
      2 and on day 21 of cycle 4 (end of therapy) for the primary study aim. Patients will be&#xD;
      treated under study conditions for a maximum of 4 therapy cycles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized Phase IV study. Patients who progressed after one&#xD;
      chemotherapy in the metastatic setting will be randomized 1:1 to one of the following&#xD;
      treatment arms. Arm A. Eribulin 1.23 mg/m2 on days 1 and 8 q21d Arm B. Paclitaxel 80 mg/m2 on&#xD;
      days 1, 8, and 15 q21d Blood draws for immune analysis will be performed before start of&#xD;
      therapy on day 1 of cycle 1, on day 1 of cycle 2 (pre dose each) and on day 21 of cycle 4&#xD;
      (end of therapy) and assessed for the primary study aim. Patients will be treated under study&#xD;
      conditions for a maximum of 4 therapy cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune responsivity (IR)</measure>
    <time_frame>12 weeks after therapy start</time_frame>
    <description>defined as ≥ 5% of all T cells from peripheral blood are Ki-67 positive after chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response after three months</measure>
    <time_frame>three months after therapy start</time_frame>
    <description>Overall response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and safety of eribulin and paclitaxel</measure>
    <time_frame>Therapy start until 30 days post last dose</time_frame>
    <description>Toxicity and safety of eribulin and paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQC30</measure>
    <time_frame>Therapy start until therapy end after 4 cycles up to 12 weeks</time_frame>
    <description>Quality of life assessed via EORTC QLQC30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Neoplasm, Breast</condition>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Eribulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A. Eribulin 1.23 mg/m^2, administered as an injection on day 1 and 8 q 21d for a maximum of 4 therapy cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 80 mg/m^2, administered as an injection on day 1, 8 and 15 q21d for a maximum of 4 therapy cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin Injection [Halaven]</intervention_name>
    <description>on days 1 and 8 q21d</description>
    <arm_group_label>Eribulin</arm_group_label>
    <other_name>Eribulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel injection</intervention_name>
    <description>on days 1, 8, and 15 q21d</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent prior to beginning of trial specific procedures&#xD;
&#xD;
          -  Subject must be female and aged ≥ 18 years on day of signing informed consent&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Histologically confirmed, HER2 negative breast cancer determined by core biopsy of&#xD;
             tumor lesion. Human epidermal growth factor receptor 2 (HER2) negativity is defined as&#xD;
             either of the following by local laboratory assessment: In situ hybridization (ISH)&#xD;
             non-amplified (ratio ≤ 2.2), or IHC 0 or IHC 1+.&#xD;
&#xD;
          -  Indication for chemotherapy&#xD;
&#xD;
          -  Previous therapy with one chemotherapy line&#xD;
&#xD;
          -  Target lesion (RECIST 1.1)&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
        Creatinine Clearance &gt; 50 ml/min ANC ≥ 1.5 x 10 3 /μL Thrombocytes &gt; 100 x 10 3 /μL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HER2 positive disease&#xD;
&#xD;
          -  Indication for an anti-hormone treatment&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Active autoimmune disease or other diseases that requires systemic treatment with&#xD;
             corticosteroids or immunosuppressive drugs.&#xD;
&#xD;
          -  History of primary or acquired immunodeficiency (including allogenic organ&#xD;
             transplant).&#xD;
&#xD;
          -  Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,&#xD;
             ulcerative colitis).&#xD;
&#xD;
          -  Severely impaired liver function (Child Pugh C)&#xD;
&#xD;
          -  Hypersensitivity to study medication or any of its components&#xD;
&#xD;
          -  Neuropathy (PNP) &gt; Grade 2 (CTCAE 5.0)&#xD;
&#xD;
          -  Congenital long QT syndrome&#xD;
&#xD;
          -  Preexisting concomitant use of strong CYP3A4 and CYP2C8 inhibiting or inducing drugs&#xD;
&#xD;
          -  Life expectancy of less than three months&#xD;
&#xD;
          -  Pregnancy (contraception is required according tocontraceptive guidance)&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Known history of following infections: Human immunodeficiency virus (HIV), History of&#xD;
             acute or chronic Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Has received a live-virus vaccination within 30 days of planned treatment start.&#xD;
             Seasonal flu vaccines that do not contain live virus are permitted.&#xD;
&#xD;
          -  Does not agree to blood collection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Fasching, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Gynecology and Obstetrics, Erlangen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AIRE Study manager</last_name>
    <phone>+49 (0) 9131 927 9578</phone>
    <email>aire@ifg-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gynecology, Tübingen University Hospital</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hartkopf, MD, Prof.</last_name>
      <phone>+49 07071 29 82211</phone>
      <email>andreas.hartkopf@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics, Erlangen University Hospital</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter A Fasching, Prof. Dr.</last_name>
      <phone>+49 9131 85</phone>
      <phone_ext>43470</phone_ext>
      <email>peter.fasching@uk-erlangen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunoresponse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

